Products for Research Use Only

Fresolimumab

CAT: 0804-HY-P99020-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99020-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin -induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease[1][2][3][4].
CAS Number
948564-73-6
Product Name Alternative
GC1008
UNSPSC
12352203
Target
TGF-beta/Smad
Type
Inhibitory Antibodies
Related Pathways
Stem Cell/Wnt; TGF-beta/Smad
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/fresolimumab.html
Purity
99.51
Solubility
H2O
Smiles
[Fresolimumab]
Molecular Weight
(144.4 kDa)
References & Citations
[1]Song IW, et al. Targeting TGF-β for treatment of osteogenesis imperfecta. J Clin Invest. 2022 Apr 1;132 (7) :e152571.|[2]Lan Y, et al. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses. J Immunother Cancer. 2022 Jul;10 (7) :e004122.|[3]Oude Munnink TH, et al. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models. J Nucl Med. 2011 Dec;52 (12) :2001-8.|[4]Kadam AH, et al. Targeting caveolae to pump bispecific antibody to TGF-β into diseased lungs enables ultra-low dose therapeutic efficacy. PLoS One. 2022 Nov 22;17 (11) :e0276462.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2

Popular Products